German biotech company T-CURX GmbH has announced the first closing of a $20M (€17.7M) Series A financing round to accelerate clinical development of its non-viral CAR-T cell therapies and advance proprietary in vivo CAR-T generation technologies. The funding round was led by BiomedVC, with participation from Bayern Kapital, HighLight Capital, i&iBio Fund, and existing and […]
The Wellcome Sanger Institute has selected Sapio Sciences’ informatics platform as its central laboratory information management system (LIMS) to support a comprehensive digital transformation programme aimed at unifying genomics workflows across the organisation.
Clinical Experts Issue Special Report Calling for Greater Education, Testing, and Prevention of In Vitro Hemolysis in High-Risk Settings
Montreal-based contract research organisation Indero has completed an internally funded study demonstrating that quantitative gene expression analysis can assess topical new chemical entities in early-phase clinical research within three days, substantially reducing the time and cost associated with traditional evaluation methods.
Johnson & Johnson has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. for US$3.05 billion in cash, securing access to a clinical-stage prostate cancer therapy and a proprietary platform technology designed to develop oral targeted treatments for solid tumours. The transaction is expected to close within the coming months pending antitrust clearance […]
St. Jude Children’s Research Hospital scientists have launched AlphaSync, a free database addressing a critical gap in structural biology by continuously synchronising predicted protein structures with the latest sequence data from UniProt. The resource currently provides 2.6 million updated structural models across 925 species, including disease-relevant proteins previously missing from existing databases.
A Finnish biotechnology company has opened applications for a global scientific competition designed to advance understanding of cellular redox metabolism, offering successful applicants access to precision measurement technology and expert support valued at up to $30,000.
Chromsystems announces the launch and immediate availability of the MassTox® TDM Series A Parameter Set Antiepileptic Drugs XT2 in Serum/Plasma – All-in-One Method. The updated parameter set extends the MassTox® TDM portfolio, helping laboratories meet clinical needs and regulatory requirements in therapeutic drug monitoring.
Discover the perfect solution for every laboratory size. Due to its compact design respons®240c is ideal for small labs that require an analyzer capable of a constant throughput of 240 tests/hour along with intuitively operated software. Advanced features like onboard hemolysis and a grated photometer with 12 wavelengths ensure precision and efficiency.
MassTox® TDM Series A
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.